The drug, which was jointly developed by Sanofi and the US biotechnology firm Regeneron to treat rheumatoid arthritis, is part of a global program of clinical trials for patients with severe forms of coronavirus disease.
Regeneron leads the tests in the United States and Sanofi takes care of the tests outside the American territory.
Some 300 critically or critically ill patients will participate in the trials, the agency said.
Helping patients with acute respiratory distress
Authorized in several countries for the treatment of active rheumatoid arthritis, Kevzara inhibits interleukin 6 (IL-6) which could play a role in the inflammatory immune response causing the acute respiratory distress syndrome observed in patients with a severe form of Covid-19.
Like most medicines, Kevzara has contraindications. According to a document published on the Sanofi website, Kevzara can reduce the body’s ability to fight infections, cause neutropenia (low white blood cells) and gastrointestinal complications.
On March 11, the World Health Organization (WHO) called the outbreak of Covid-19 disease caused by the new coronavirus SARS-CoV-2 pandemic.
According to the latest WHO figures, more than 657,140 people were infected worldwide and more than 30,450 died on March 29.